The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis.
 
Vicky Makker
Consulting or Advisory Role - ArQule; Clovis Oncology; DualityBio; Eisai; Faeth Therapeutics; GlaxoSmithKline; IBM; ITeos Therapeutics; Kartos Therapeutics; Karyopharm Therapeutics; Lilly; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); DualityBio (Inst); Eisai (Inst); Faeth Therapeutics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Eisai; ESMO Congress; Merck
Other Relationship - IBM
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Immunogen; Mersana; ProfoundBio
Research Funding - Aravive (Inst); Arch Oncology (Inst); ArQule (Inst); AstraZeneca (Inst); Celsion (Inst); Clovis Oncology (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Plexxikon (Inst); Roche (Inst); Shattuck Labs (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Hye Sook Chon
Honoraria - Curio Science; Envision Communications; Guidepoint Global; MJH Healthcare Holdings, LLC
Consulting or Advisory Role - Eisai; Envision Communications
Speakers' Bureau - Clinical Care Options
Travel, Accommodations, Expenses - Agenus
 
David Scott Miller
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Asymmetric Therapeutics; BOSTON BIOMEDICAL RESEARCH INSTITUTE; Clinical Education Alliance; Eisai; Eisai; EMD Serono; GlaxoSmithKline; GlaxoSmithKline; Immunogen; Incyte; Incyte; ITeos Therapeutics; Karyopharm Therapeutics; Merck Sharp & Dohme; Myriad Genetic Laboratories; Novartis; Novocure; Seagen; Tarveda Therapeutics
Research Funding - Advaxis (Inst); Advenchen Laboratories (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Akeso Biopharma (Inst); Aprea AB (Inst); AstraZeneca (Inst); EMD Serono; Immunogen (Inst); Incyte (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics; Mateon Therapeutics (Inst); Merck Sharp & Dohme (Inst); Millenium Pharamceuticals (Inst); Novartis (Inst); NVision (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); TRACON Pharma (Inst); US Biotest (Inst); Xenetic Biosciences (Inst)
 
Morten Mau-Sørensen
No Relationships to Disclose
 
David Cibula
Consulting or Advisory Role - Akeso Biopharma; AstraZeneca; GlaxoSmithKline; Mersana; MSD; Novocure; Roche; Sotio
 
Flora Zagouri
Honoraria - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD; Novartis; Pfizer Hellas; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo Europe GmbH; Genesis Pharma; Gilead Sciences; Lilly; Merck; MSD Oncology; Novartis; Pfizer Hellas; Roche
 
Alejandro Pérez Fidalgo
Consulting or Advisory Role - Abilify; AstraZeneca; Clovis Oncology; GlaxoSmithKline; Roche
Speakers' Bureau - AstraZeneca; Clovis Oncology; GlaxoSmithKline; PharmaMar
Research Funding - GlaxoSmithKline (Inst); PharmaMar (Inst)
Expert Testimony - Samsumg Pharm
 
Brian M. Slomovitz
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Eisai; EQRx; Genentech; Genmab; Gilead Sciences; GlaxoSmithKline; GOG Foundation; Lilly; Merck; Nuvation Bio; Onconova Therapeutics; Onconova Therapeutics; Regeneron; Seagen
 
Robert L. Coleman
Employment - US Oncology; Vaniam Group
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson/US Oncology Network
Consulting or Advisory Role - Abbvie; Agenus; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck; Novocure; OncoMed; OncXerna Therapeutics
Research Funding - Alkermes; Amgen (Inst); AstraZeneca/MedImmune; Clovis Oncology (Inst); Immunogen (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck; Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (I)
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group
 
Pratheek Kalyanapu
Employment - Karyopharm Therapeutics
 
Rong Fan
Employment - Karyopharm Therapeutics
 
Girish Gudi
Employment - Karyopharm Therapeutics
 
Ignace Vergote
Consulting or Advisory Role - Agenus; Akeso Biopharma; AstraZeneca; Bristol Myers Squibb; Deciphera; Eisai; Elevar Therapeutics; Exelixis; Genmab; GlaxoSmithKline; Immunogen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Mersana; MSD; Novartis; Novocure; Oncoinvent; OncXerna Therapeutics; Regeneron; Roche; Sanofi; Seagen; Sotio; Verastem; Zentalis
Research Funding - Amgen (Inst); Oncoinvent (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Genmab; Karyopharm Therapeutics; Novocure